When does this change take effect?

This change is effective Jul 9, 2025.

Back to dashboard

CommercialCoverageMedium impact

07.00.10j, Photodynamic Therapy (PDT) Using Porfimer Sodium (Photofrin®)

Q: Who is affected by this change?

This affects Independence Blue Cross Dermatology, Oncology, Ophthalmology providers on Commercial plans.

Independence Blue Cross·Dermatology, Oncology, Ophthalmology·Pharmacy

Effective date

Jul 9, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

The Photodynamic Therapy (PDT) Using Porfimer Sodium (Photofrin®) pharmacy policy has been reissued with updates for commercial plans. This is a fresh policy update that may affect billing and coverage for PDT procedures, though specific changes are not detailed in the summary provided.

Action Required

Action needed

By July 9, 2025: Billing team should review the full updated policy at the provided URL to identify specific changes to PDT billing requirements, coverage criteria, or prior authorization needs. Update billing procedures and documentation requirements as specified in the complete policy.

Related policy hubs

Independence Blue Cross policies Dermatology Oncology Ophthalmology